NASDAQ$LNAI
Lunai Bioworks Inc · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
Renovaro reported a net income for Q3 2025, a significant improvement from a net loss in the prior year, driven by a positive change in the fair value of contingent consideration and reduced operating expenses.
Renovaro Inc. reported a net income of $189,176 for the three months ended March 31, 2025, a substantial improvement compared to a net loss of $(58,990,070) in the same period last year. This positive shift was primarily due to a significant change in the fair value of contingent consideration and a decrease in overall operating expenses, despite no revenue generation.
- Renovaro achieved a net income of $189,176 in Q3 2025, a significant turnaround from a net loss of $(58,990,070) in Q3 2024.
- Operating expenses decreased by 92% to $4,162,492, largely due to a reduction in intangible asset impairment.
- The company reported a positive change in the fair value of contingent consideration of $4,330,000, compared to a negative change of $(7,289,156) in the prior year.
- Cash and cash equivalents increased to $923,002 as of March 31, 2025, up from $220,467 at June 30, 2024.
Headline financials
Revenue & EPS history
Renovaro · Revenue · Quarterly
$0
Forward guidance
Renovaro Inc. anticipates continued losses until therapies or products are approved for marketing and sale. The company plans to secure additional funding through equity or debt financing to support commercialization, clinical and regulatory work, and build working capital reserves.
Tailwinds
- Focus on AI-driven cancer diagnostics platform development and validation.
- Intention to secure additional funding through equity or debt financing.
- Funding expected to satisfy existing and future obligations and working capital needs.
- Support for commercialization of products and clinical/regulatory work for product candidates.
- Plans to build working capital reserves.
Headwinds
- No sales revenue generated to date, and none anticipated until product approval.
- Uncertainty regarding the availability of additional funding on reasonable terms.
- Potential for significant additional dilution to stockholders from equity financing.
- Risk of depletion of cash resources and potential suspension of operations without additional funding.
- Adverse outcomes in legal or regulatory proceedings could negatively impact liquidity and financial position.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2025
+2.0%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+6.9%
Avg return
30 days after
44%
16 / 36 earnings
Positive
+36.6%
Q4 2024
Best reaction
-17.8%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | -7.3% | -18.5% | +9.3% | |
| Q2 2026 | -9.1% | -25.7% | -47.5% | |
| Q1 2026 | +5.1% | +45.6% | +3.9% | |
| Q4 2025 | +30.1% | +1.6% | -25.9% | |
| Q3 2025 | -1.6% | -9.4% | -8.4% | |
| Q2 2025 | -0.9% | -10.1% | -18.5% | |
| Q1 2025 | -17.8% | -21.4% | +192.4% | |
| Q4 2024 | +36.6% | +68.6% | +51.0% | |
| Q3 2024 | -15.3% | -6.7% | +57.7% | |
| Q2 2024 | +4.2% | +18.2% | +65.1% | |
| Q1 2024 | -4.0% | -6.7% | +12.8% | |
| Q4 2023 | +1.8% | +2.9% | -35.1% | |
| Q3 2023 | -3.4% | -16.4% | -36.8% | |
| Q2 2023 | -1.8% | -5.5% | -1.8% | |
| Q1 2023 | -6.0% | -7.8% | -7.8% | |
| Q4 2022 | -12.5% | -9.4% | -35.4% | |
| Q3 2022 | -5.9% | -7.5% | -40.8% | |
| Q2 2022 | +9.9% | +24.0% | +6.7% | |
| Q1 2022 | +7.9% | +11.0% | -18.6% | |
| Q4 2021 | +6.0% | -7.5% | +14.8% | |
| Q4 2020 | -1.6% | -3.1% | -2.4% | |
| Q3 2021 | -6.9% | +1.3% | +58.5% | |
| Q2 2021 | +11.4% | +5.9% | -8.6% | |
| Q2 2020 | -2.2% | +7.1% | +17.3% | |
| Q1 2021 | -0.7% | +2.3% | -2.3% | |
| Q1 2020 | -4.3% | -4.6% | -17.6% | |
| Q4 2019 | +4.8% | +2.5% | -2.8% | |
| Q3 2020 | +4.5% | +12.4% | +28.6% | |
| Q2 2019 | +4.8% | -4.8% | -4.0% | |
| Q1 2019 | +15.5% | +2.6% | +31.3% | |
| Q4 2018 | -0.9% | +4.4% | +8.9% | |
| Q3 2018 | -1.2% | -0.3% | -11.4% | |
| Q2 2018 | +0.7% | +1.0% | -8.2% | |
| Q1 2018 | +0.9% | -0.7% | -2.1% | |
| Q4 2017 | +29.5% | +32.5% | +20.5% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2017 | +0.0% | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro